Description
SWOT ANALYSIS OF RANBAXY
Ranbaxy
Parent Company
Ranbaxy
Category
Pharmaceuticals
Sector
Health care
Tagline/ Slogan
New boundaries, new Horizons; Trusted medicines healthier lives
USP
It is India’s largest pharmaceutical company
STP
Anti-Infectives, Cardiovascular & Diabetes, Dermatological, NeuroSegment Psychiatry, Pain management, Gastro-Intestinal, Nutritional
Healthcare professionals, wholesalers, generic distributors, and Target Group hospitals
Positioning
A diversifies global healthcare company focused on patient’s needs
SWOT Analysis
1.Top 10 Global Generic Company with a spread over 125 countries 2. over 13,000 well trained Employees, over 50 nationalities 3. Strong presence in the International market with a major share and a strong presence in India as well 4.It has operations in nearly 50 countries and has 7 manufacturing Strength plants
1. It is heavily dependent upon generics for its revenue generation 2. Constantly regulated policies by the govt means operational Weakness efficiency is affected
1.increasing health awareness 2.Improvement in distribution network & brand building Opportunity 3. They can leverage Synriam, anti-malarial drug in brand building
1.Increasingly stringent FDA Regulations Threats 2.Exchange rate fluctuations
3.Global economic slowdown
Competition
1. Sun Pharma 2. Dr Reddys Labs 3. Lupin pharmaceuticals Competitors 4. Glaxosmithkline
doc_734335207.docx
SWOT ANALYSIS OF RANBAXY
Ranbaxy
Parent Company
Ranbaxy
Category
Pharmaceuticals
Sector
Health care
Tagline/ Slogan
New boundaries, new Horizons; Trusted medicines healthier lives
USP
It is India’s largest pharmaceutical company
STP
Anti-Infectives, Cardiovascular & Diabetes, Dermatological, NeuroSegment Psychiatry, Pain management, Gastro-Intestinal, Nutritional
Healthcare professionals, wholesalers, generic distributors, and Target Group hospitals
Positioning
A diversifies global healthcare company focused on patient’s needs
SWOT Analysis
1.Top 10 Global Generic Company with a spread over 125 countries 2. over 13,000 well trained Employees, over 50 nationalities 3. Strong presence in the International market with a major share and a strong presence in India as well 4.It has operations in nearly 50 countries and has 7 manufacturing Strength plants
1. It is heavily dependent upon generics for its revenue generation 2. Constantly regulated policies by the govt means operational Weakness efficiency is affected
1.increasing health awareness 2.Improvement in distribution network & brand building Opportunity 3. They can leverage Synriam, anti-malarial drug in brand building
1.Increasingly stringent FDA Regulations Threats 2.Exchange rate fluctuations
3.Global economic slowdown
Competition
1. Sun Pharma 2. Dr Reddys Labs 3. Lupin pharmaceuticals Competitors 4. Glaxosmithkline
doc_734335207.docx